Engineered monoclonal antibody tobevibart enhances HBsAg capture by Fc receptor-positive cells and activates HBV-specific T cells

Journal:

Journal of Hepatology

Published:

2025-08-28

DOI:

10.1016/j.jhep.2025.08.016

Affiliations:

11

Authors:

34

Go to article

Institutions	Authors	Share
Vir Biotechnology, United States of America (USA)	18.500000 18.500000	0.54
Vir Biotechnology Switzerland, Switzerland	10.500000 10.500000	0.31
The University of Auckland, New Zealand	1.000000	0.03
King's College Hospital, King's College Hospital NHS Foundation Trust, United Kingdom (UK)	1.000000	0.03
Hannover Medical School (MHH), Germany	1.000000	0.03
The University of Utah (Utah), United States of America (USA)	1.000000	0.03
Queen Mary Hospital (QMH), China	0.500000	0.01
The University of Hong Kong (HKU), China	0.500000	0.01

Interested in Medical Microbiology?